Clinical efficacy of montelukast in anti-inflammatory treatment of asthma and allergic rhinitis
|
|
- Scott Edwards
- 5 years ago
- Views:
Transcription
1 Clinical efficacy of montelukast in anti-inflammatory treatment of asthma and allergic rhinitis Kim Hyun Hee, MD, PhD. Dept. of Pediatrics The Catholic University of Korea College of Medicine
2 Achieving asthma control In Real-world Understanding the reason for poor control
3 Uncontrolled Asthma Heavy burden on patients and their families Increased rates of hospitalizations and emergency room and other urgent care visits Activity limitations Night time awakenings Lost time from work and school Expensive, counting for most of asthma related health care cost
4 Need for Changes in Asthma Management - A Real Life Issue Many asthma patients remain uncontrolled: 94.7% did not meet all GINA criteria for asthma control a (AIRE Study) 1 51% did not meet criteria for asthma control despite the use of an ICS or an ICS + LABA (INSPIRE study) 2 a At the time of this study, GINA criteria for asthma control included the following: minimal chronic symptoms, minimal exacerbations, no emergency visits, minimal need for as-needed β agonists, no limitations in daily activities, and normal or near-normal lung function. GINA=Global Initiative for Asthma; AIRE=Asthma Insights and Reality in Europe; ICS=inhaled corticosteroids; LABA=long-acting β-agonists; INSPIRE=International Asthma Patient Insight Research. 1. Rabe KF et al. Eur Respir J. 2000;16: Partridge MR et al. BMC Pulm Med. 2006;6:13. doi: / Thomas M et al. Pediatrics. 2005;115(1): Kang H-Y et al. Yonsei Med J. 2008;49(4): Price D et al. Clin Exp Allergy. 2005;35: LaForest L et al. Int Arch Allergy Immunol. 2005;136: Valovirta E et al. BMC Pulm Med. 2006;6(suppl 1):S3. Slide 4
5 Predicting Poor Asthma Control 1 The wrong diagnosis Incorrect choice of inhaler or poor inhaler technique Smoking Patients beliefs and adherence Co-morbid rhinitis Individual variation in response to treatment 1. Achieving asthma control in practice: Understanding the reasons for poor control, Respiratory Medicine (2008) 102, 1681e1693
6 Predicting Poor Asthma Control 1 The wrong diagnosis Incorrect choice of inhaler or poor inhaler technique Smoking Patients beliefs and adherence Co-morbid rhinitis Individual variation in response to treatment 1. Achieving asthma control in practice: Understanding the reasons for poor control, Respiratory Medicine (2008) 102, 1681e1693
7 Smoking adversely impacts asthma control The prevalence of current smoking among patients with asthma varies by country from 15% to 25% 1,2 In retrospective cohort study of a large UK general practice database, Current smokers were almost 3 times more likely than non-smokers to be hospitalized for their asthma over a 12-month period 3 1. Annesi-Maesano I, Oryszczyn MP, Raherison C, et al. Increased prevalence of asthma and allied diseases among active adolescent tobacco smokers after controlling for passive smoking exposure. Clin Exp Allergy 2004; 34(7): Hylkema MN, Sterk PJ, de Boer WI, Postma DS. Tobacco use in relation to COPD and asthma. Eur Respir J 2007;29(3): Price D, Zhang Q, Kocevar VS, Yin DD, Thomas M. Effect of a concomitant diagnosis of allergic rhinitis on asthma related healthcare use by adults. Clin Exp Allergy 2005;35 (3): 282-7
8 Smoking adversely impacts asthma control Barnes PJ et al. Lancet 2004;363:731-3
9 FEV 1, L Asthma Control Score Cigarette Smoking and Asthma Variability: Reduced Response to Oral Corticosteroids Placebo Prednisolone 3.0 P=0.605 P=0.386 P= P=0.865 P=0.108 P= Smokers n=14 Ex-Smokers n=10 Never-Smokers n=26 Smokers n=14 Ex-Smokers n=10 Never-Smokers n=26 1. Chaudhuri R et al. Am J Respir Crit Care Med. 2003;168: , with permission from the American Thoracic Society. Slide 9
10 ICS therapy in Asthmatic smokers ICS therapy fails more often in smokers due to Different pattern of airway inflammation- neutrophilic inflammation Oxidative stress production which impairs the activity of HDAC2 Leukotriene production Fig. 1. Peak Expiratory Flow in non-smoking and smoking patients Fig.2. co-relation between smoking & urinary LTE4 1. Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma. Thorax 2002;57(3):226e30 (Fig. 1) 2. Cigarette smoking stimulates cysteinyl leukotriene production in man. Fauler J. and Frölich J.C. Eur J Clin Invest 1997; 27: (Fig. 2)
11 Higher LTE 4 concentration in Asthmatic smokers The level of LTE 4 / creatinine (pg/mg) were increased in asthmatic subjects compared to COPD and controls, p< for asthma (Fig. 1) The level of LTE 4 / creatinine (pg/mg) were increased in asthmatic smokers compared to non-smokers, P< (Fig. 2) Fig. 1. LTE4/creatinine concentration between control subjects Fig. 2. LTE4/creatinine concentration between control subjects 1. Gaki E, Papatheodorou G et al. Leukotriene E4 in urine in patients with asthma and COPD- effect of smoking habit, Resp Medicine 2008 Each symbol represents one individual. Horizontal bars represent mean values. S: smoking, NS: non-smoking, ES: Ex-smoking.
12 am PEF (L/min) Greater response of Montelukast in Smokers Montelukast showed greater response than ICS in asthmatic smokers ** *** * Montelukast Beclomethasone Non-Smokers Smokers N=83 1. Smoking affects response to inhaled corticosteroids or leukotriene receptor antagonists in asthma. Am J Respir Crit Care Med. 2007;175: AJRCCM 2006
13 Role of LTRA in Asthmatic Smokers The LTRA montelukast seems to have some effect in smokers with asthma, as shown by a recently performed pilot study These results need to be confirmed in larger clinical trials
14 Predicting Poor Asthma Control 1 The wrong diagnosis Incorrect choice of inhaler or poor inhaler technique Smoking Patients beliefs and adherence Co-morbid rhinitis Individual variation in response to treatment 1. Achieving asthma control in practice: Understanding the reasons for poor control, Respiratory Medicine (2008) 102, 1681e1693
15 Predicting Poor Asthma Control 1 The wrong diagnosis Incorrect choice of inhaler or poor inhaler technique Smoking Patients beliefs and adherence Co-morbid rhinitis Individual variation in response to treatment 1. Achieving asthma control in practice: Understanding the reasons for poor control, Respiratory Medicine (2008) 102, 1681e1693
16 Number of Subjects (n=72) PRICE Results: 6-Week ICS Period FEV 1, % Change a 3 54% of subjects determined to be responders (n=39) 46% of subjects categorized as non-responders (n=33) 1 1 Baseline Parameters b FEV 1 % predicted Responders (n=39) Non-responders (n=33) P Value 68.5 ± ± 8.8 <0.001 FEV 1 /FVC 0.65 ± ± 0.1 < a FEV 1 distribution response to ICS over short-term 6-week trial. Bars represent 5% increments in FEV 1 response. b Mean ± standard deviation. Reprinted from Martin RJ et al. The Predicted Response to Inhaled Corticosteroid Efficacy (PRICE) trial. J Allergy Clin Immunol. 2007;119: Copyright 2007 American Academy of Allergy, Asthma & Immunology, with permission from Elsevier. Slide 16
17 PRICE Results: 16-Week Double-Blind Trial a Responders: Those who remained on ICS treatment maintained asthma control. Those randomized to placebo had worse asthma control. Non-responders: It did not matter whether patients continued ICS treatment or switched to placebo. ACQ results did not differ between treatment groups. ACQ=asthma control questionnaire. a Asthma control measured by mini ACQ and stratified by FEV 1 response. Martin RJ et al. J Allergy Clin Immunol. 2007;119: Slide 17
18 CLIC Primary Outcome: FEV 1 Response FEV 1 Change With Montelukast Sodium 7.5% MT response Concordance Correlation 0.55 (0.43, 0.65) Montelukast sodium alone n=6 (5%) Both medications n=22 (17%) Multicenter, randomized, double-blind, cross-over Primary long-term Tx for ped asthma N = 144, 6~17yr 16wks, cross-over MONK 5mg vs FP 100mg bid inh Neither medication n=69 (55%) Fluticasone propionate alone n=29 (23%) 7.5% FP response FEV 1 Change With Fluticasone Propionate MT=montelukast sodium; FP=fluticasone propionate. Reprinted from Szefler SJ et al. J Allergy Clin Immunol. 2005;115: , with permission from the American Academy of Allergy, Asthma, and Immunology. Slide 18
19 CLIC: Difference in Asthma Control (Days-per-Week Response) a Participants Better response to fluticasone propionate (n=36) Better response to montelukast sodium (n=15) a Difference in asthma control days between fluticasone propionate and montelukast sodium (fluticasone minus montelukast sodium) for individual participants. Each line designates a single participant. An asthma control day was defined as a day with no daytime or nighttime asthma symptoms, no rescue albuterol for asthma symptoms or peak flow less than 80% of personal best, no asthma health care use, and no asthma-related absences from school or work. Reprinted from Zeiger RS et al. J Allergy Clin Immunol. 2006;117:45 52, with permission from the American Academy of Allergy, Asthma, and Immunology. Slide 19
20 Summary in variability in Tx response Clinicians should expect variability in treatment response to clinical, physiologic, and inflammatory indicators of response for ICSs and LTRAs in all patients incl. children and adults Low pulmonary function, bronchodilator response and airway hyperresponsiveness are associated with a favorable response to ICS eno level are associated with a favorable response to ICSs in children but not adults Younger age, higher urinary leukotriene levels and shorter duration of disease are linked to a favorable response to LTRAs in children Adult patients with asthma who smoke might have a favorable response to LTRAs over ICSs
21 The MONtelukast In Chronic Asthma (MONICA) study Efficacy of montelukast in asthma patients inadequately controlled on an ICS or an ICS + LABA Slide 21
22 MONICA 1 Study Design and Methods Design Multicenter, open-label, prospective study Objective To assess the impact of montelukast added to an ICS or an ICS + LABA in patients with uncontrolled asthma Setting Subjects recruited by office-based pulmonary specialists at 290 sites in Germany Patient population Patients aged 18 years with mild to moderate persistent asthma uncontrolled by ICS or ICS + LABA therapy Treatment 6 months of therapy with montelukast 10 mg once daily in addition to current asthma treatment a a Concomitant medications included short-acting β-agonists, ICS, LABA, fixed combinations of ICS and LABA, theophylline, or, in some cases, oral corticosteroids. 1. Virchow JC et al. Respir Med. doi: /j.rmed Slide 22
23 MONICA 1 Effective End Points Primary ACT scores Secondary German version of the validated MiniAQLQ Other Lung function (assessed by FEV 1 and PEF) ACT=asthma control test; MiniAQLQ=MiniAsthma Quality of Life Questionnaire. 1. Virchow JC et al. Respir Med. doi: /j.rmed Slide 23
24 MONICA 1 Baseline Characteristics of Patients Characteristic Value Total number of patients treated 1,681 Mean ± SD age, y 45.7 ± 15.9 Men, % of patients 34 Women, % of patients 66 Lung function (FEV 1 or PEF) <80% of predicted, % of patients 36 Daytime symptoms >2 times/week, % of patients 72 Rescue medication use >2 times/week, % of patients 57 Exacerbations 1x/y, % of patients 45 Uncontrolled asthma despite ICS or ICS + LABA, % of patients 95 SD=standard deviation. 1. Virchow JC et al. Respir Med. doi: /j.rmed Slide 24
25 Patients in Each ACT Category, % MONICA 1 Improvements in ACT Scores With Add-On Montelukast ACT Scores 25 (Completely controlled) (Well controlled) (Poorly controlled) <16 (Uncontrolled) Baseline (n=1,681) 21.0 Month 3 (n=1,477) Primary end point: Mean ACT score improved significantly between baseline (14.6 ± 4.6) and Month 6 (19.4 ± 4.4) with add-on montelukast (P<0.0001). 1. Virchow JC et al. Respir Med. doi: /j.rmed Month 6 (n=1,303) Slide 25
26 Mean Score MONICA 1 Improvements in MiniAQLQ With Add-On Montelukast 6 5 Baseline (n=1,605) Month 3 (n=1,409) Month 6 (n=1,261) 5.0 a 5.3 a ICS or ICS + LABA ICS or ICS + LABA + Montelukast ICS or ICS + LABA + Montelukast a P< vs baseline. 1. Virchow JC et al. Respir Med. doi: /j.rmed Slide 26
27 FEV 1, L PEF, L/s MONICA 1 Improvements in Lung Function With Add-On Montelukast Baseline Month 3 Month a 2.60 a a 6.22 a a P< vs baseline. (n=1,445) (n=1,057) (n=914) ICS or ICS + LABA ICS or ICS + LABA + Montelukast ICS or ICS + LABA + Montelukast 1 0 (n=967) (n=669) (n=563) ICS or ICS + LABA ICS or ICS + LABA + Montelukast ICS or ICS + LABA + Montelukast Lung function measurements were performed at the investigator s discretion; thus, not all patients had data for these parameters. 1. Virchow JC et al. Respir Med. doi: /j.rmed Slide 27
28 Physicians/Patients at Month 6, % MONICA 1 Global Improvements in Asthma With Add-On Montelukast Very much better/better No improvement Physicians a Patients a N not stated. 1. Virchow JC et al. Respir Med. doi: /j.rmed Slide 28
29 MONICA 1 Summary and Conclusions This real-world study showed that 6 months of add-on therapy with montelukast was effective in patients already receiving an ICS or an ICS + LABA who had uncontrolled asthma symptoms. Asthma control (Months 3 and 6): significant improvements in ACT score (P< vs baseline) (primary end point) Quality of life (Months 3 and 6): significant improvements in the MiniAQLQ score (P< vs baseline) Lung function (Months 3 and 6): significant improvements in FEV 1 and PEF (P< vs baseline for both comparisons) Asthma status (Month 6): improvements in global assessment by 83% of patients and physicians 1. Virchow JC et al. Respir Med. doi: /j.rmed Slide 29
30 The MARS study (Montelukast combined with fixed Associations in Real life Survey) Efficacy of montelukast in asthma patients inadequately controlled on an ICS + LABA Slide 30
31 MARS 1 Study Design and Methods Design Multicenter, open-label, prospective, observational study Objective Evaluate the impact of add-on therapy with montelukast in patients with asthma who were uncontrolled on current ICS + LABA treatment a Setting Outpatients enrolled by general practitioners in Belgium Patient population Patients 4 years of age with mild to moderate asthma who were symptomatic despite ICS + LABA therapy Treatment 2 months of montelukast 4 mg, 5 mg, or 10 mg once daily at bedtime added to an ICS + LABA a Budesonide + formoterol turbohaler or fluticasone + salmeterol dry-powder inhaler. 1. Korn D et al. Curr Med Res Opin. 2009;25(2): Slide 31
32 MARS 1 Efficacy End Point Primary End Point: Change in mean ACQ score a from baseline to Month 2 Subgroup analyses of change in mean ACQ score based on Presence of allergic rhinitis symptoms ICS + LABA dose level Type of ICS + LABA combination ACQ=Asthma Control Questionnaire. a ACQ score calculated as the sum of 6 items on a questionnaire rated from 0 (best) to 6 (worst). 1. Korn D et al. Curr Med Res Opin. 2009;25(2): Slide 32
33 MARS Baseline 1 Characteristics of Patients Characteristic Value Total number of patients evaluated 5,769 Mean ± SD age, y 41 ± 21 Patients aged <15 y, % 14.3 Patients aged 15 y, % 85.7 Males, % of patients 53 Females, % of patients 47 Patients with concomitant allergic rhinitis, % 42 ICS + LABA a dosage stratum, % of patients Low dose Medium dose High dose Patients with partially controlled b asthma, % 38 Patients with uncontrolled c asthma, % a Budesonide + formoterol turbohaler or fluticasone + salmeterol dry-powder inhaler; b ACQ score 1.50; c ACQ score > Korn D et al. Curr Med Res Opin. 2009;25(2): Slide 33
34 ACQ Score MARS Improvement 1 in ACQ Scores (Primary End Point) a Baseline (before montelukast) Month 2 (after montelukast) a P<0.001 vs baseline. N=5, Korn D et al. Curr Med Res Opin. 2009;25(2): Slide 34
35 Mean (SD) ACQ Score MARS Improvements 1 in ACQ Scores in Patients With Asthma and Allergic Rhinitis (Subgroup Analysis) 3.0 Baseline (before montelukast) Month 2 (after montelukast) a 1.5 a,b Asthma With Allergic Rhinitis (n=2,442) Asthma Without Allergic Rhinitis (n=3,327) a P<0.001 vs baseline; b P<0.001 vs patients without allergic rhinitis. N=5, Korn D et al. Curr Med Res Opin. 2009;25(2): Slide 35
36 MARS 1 Summary and Conclusions This real-world study showed that add-on therapy with montelukast was effective in achieving asthma control in patients already receiving an ICS + LABA but who were still symptomatic. Significant improvement in mean ACQ scores in the total study cohort (primary end point) (P<0.001) Significant improvement in mean ACQ scores in the following subgroups: Patients with and without allergic rhinitis at baseline (P<0.001) Patients in all strata of ICS + LABA dosage (low, medium, and high) (P<0.001) Patients receiving ICS + LABA treatment (either budesonide + formoterol turbuhaler or fluticasone + salmeterol dry-powder inhaler) (P<0.001) 1. Korn D et al. Curr Med Res Opin. 2009;25(2): Slide 36
37 Conclusion Uncontrolled asthma is highly prevalent in patients despite the use of standard asthma medications. Smoking, individual variation in response to treatment can cause poor asthma control. Several real-world efficacy studies have shown that montelukast improves asthma control in patients whose asthma symptoms are uncontrolled on an ICS or an ICS + LABA
38 Dual Pathways of Inflammation Montelukast Combined With a Steroid Affects the Dual Pathways of Inflammation CysLTs play a key role in asthmatic inflammation Steroid-sensitive mediators play a key role in asthmatic inflammation Steroids do NOT inhibit CysLT formation in the airways of asthmatic patients Montelukast blocks the effects of CysLTs Inhaled steroids block steroidsensitive mediators DUAL PATHWAY The slide represents an artistic rendition. CysLT = cysteinyl leukotriene Slide 38 Adapted from Peters-Golden M, Sampson AP J Allergy Clin Immunol 2003;111(1 suppl):s37-s42; Bisgaard H Allergy 2001;56(suppl 66):7-11.
39 Thank you for your attention!!
Dual-Controller Asthma Therapy: Rationale and Clinical Benefits
B/1 Dual-Controller Asthma Therapy: Rationale and Clinical Benefits MODULE B The 1997 National Heart, Lung, and Blood Institute (NHLBI) Expert Panel guidelines on asthma management recommend a 4-step approach
More information#1 cause of school absenteeism in children 13 million missed days annually
Asthma Update 2013 Jennifer W. McCallister, MD, FACP, FCCP Associate Professor Pulmonary & Critical Care Medicine The Ohio State University Wexner Medical Center Disclosures None 2 Objectives Review burden
More informationDual-controller therapy, or combinations REVIEW DUAL-CONTROLLER REGIMENS I: DATA FROM RANDOMIZED, CONTROLLED CLINICAL TRIALS.
DUAL-CONTROLLER REGIMENS I: DATA FROM RANDOMIZED, CONTROLLED CLINICAL TRIALS Samy Suissa, PhD ABSTRACT Dual-controller therapy, or combinations of 2 or more pharmacotherapies with complementary mechanisms
More informationSearching for Targets to Control Asthma
Searching for Targets to Control Asthma Timothy Craig Distinguished Educator Professor Medicine and Pediatrics Penn State University Hershey, PA, USA Inflammation and Remodeling in Asthma The most important
More informationDo We Need Biologics in Pediatric Asthma Management?
Do We Need Biologics in Pediatric Asthma Management? Ting Fan LEUNG, MBChB, MD, FRCPCH, FAAAAI Professor and Chairman Department of Paediatrics The Chinese University of Hong Kong Asthma and Allergy by
More informationLearning the Asthma Guidelines by Case Studies
Learning the Asthma Guidelines by Case Studies Timothy Craig, DO Professor of Medicine and Pediatrics Distinguished Educator Penn State University Hershey Medical Center Objectives 1. Learn the Asthma
More informationScottish Medicines Consortium
Scottish Medicines Consortium montelukast 10mg tablets (Singulair ) No. (185/05) Merck, Sharp & Dohme Ltd (MSD) New indication: for asthmatic patients in whom montelukast is indicated in asthma, montelukast
More informationPredicting, Preventing and Managing Asthma Exacerbations. Heather Zar Department of Paediatrics & Child Health University of Cape Town South Africa
Predicting, Preventing and Managing Asthma Exacerbations Heather Zar Department of Paediatrics & Child Health University of Cape Town South Africa Asthma exacerbations Predicting exacerbation recognising
More informationTreatment Responses. Ronald Dahl, Aarhus University Hospital, Denmark
Asthma and COPD: Are They a Spectrum Treatment Responses Ronald Dahl, Aarhus University Hospital, Denmark Pharmacological Treatments Bronchodilators Inhaled short-acting β -Agonist (rescue) Inhaled short-acting
More informationGINA. At-A-Glance Asthma Management Reference. for adults, adolescents and children 6 11 years. Updated 2017
GINA At-A-Glance Asthma Management Reference for adults, adolescents and children 6 11 years Updated 2017 This resource should be used in conjunction with the Global Strategy for Asthma Management and
More informationType of intervention Treatment. Economic study type Cost-effectiveness analysis.
Cost-effectiveness of salmeterol/fluticasone propionate combination product 50/250 micro g twice daily and budesonide 800 micro g twice daily in the treatment of adults and adolescents with asthma Lundback
More informationTORCH: Salmeterol and Fluticasone Propionate and Survival in COPD
TORCH: and Propionate and Survival in COPD April 19, 2007 Justin Lee Pharmacy Resident University Health Network Outline Overview of COPD Pathophysiology Pharmacological Treatment Overview of the TORCH
More informationBreakfast Session Prof Neil Barnes Professor of Respiratory Medicine London Chest Hospital & The Royal London Hospital United Kingdom
Breakfast Session Prof Neil Barnes Professor of Respiratory Medicine London Chest Hospital & The Royal London Hospital United Kingdom 2 BEYOND SYMPTOMS ADDRESSING FUTURE RISK IN ASTHMA South GP CME 2013,
More informationAsthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing
Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School
More information12/18/2017. Disclosures. Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing
Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School
More informationSupplementary Medications during asthma attack. Prof. Dr Finn Rasmussen PhD. DrMedSc. Near East University Hospital North Cyprus
Supplementary Medications during asthma attack Prof. Dr Finn Rasmussen PhD. DrMedSc. Near East University Hospital North Cyprus Conflicts of Interest None Definition of Asthma Airway narrowing that is
More informationJames P. Kemp, MD; Margaret C. Minkwitz, PhD; Catherine M. Bonuccelli, MD; and Marshelle S. Warren, MD
Therapeutic Effect of Zafirlukast as Monotherapy in Steroid-Naive Patients With Severe Persistent Asthma* James P. Kemp, MD; Margaret C. Minkwitz, PhD; Catherine M. Bonuccelli, MD; and Marshelle S. Warren,
More informationUsing Patient Characteristics to Individualize and Improve Asthma Care
Using Patient Characteristics to Individualize and Improve Asthma Care Leonard B. Bacharier, M.D. Associate Professor of Pediatrics Clinical Director, Division of Allergy, Immunology, & Pulmonary Medicine
More informationBUDESONIDE AND FORMOTEROL (SYMBICORT ): Α A REVIEW
Volume 23, Issue 3 December 2007 BUDESONIDE AND FORMOTEROL (SYMBICORT ): A REVIEW Donna L. Smith, Pharm. D. Candidate More than 22 million people in the United States have asthma according to the Centers
More informationDiagnosis, Assessment, Monitoring and Pharmacological Treatment of Asthma
Diagnosis, Assessment, Monitoring and Pharmacological Treatment of Asthma Magnitude of Asthma - India Delhi Childhood asthma: 10.9% Adults: 8% Other Cities 3 to 18% Chhabra SK et al Ann Allergy Asthma
More informationControversial Issues in the Management of Childhood Asthma: Insights from NIH Asthma Network Studies
Controversial Issues in the Management of Childhood Asthma: Insights from NIH Asthma Network Studies Stanley J. Szefler, MD Helen Wohlberg and Herman Lambert Chair in Pharmacokinetics, Head, Pediatric
More informationImproving Outcomes in the Management & Treatment of Asthma. April 21, Spring Managed Care Forum
Improving Outcomes in the Management & Treatment of Asthma April 21, 2016 2016 Spring Managed Care Forum David M. Mannino, M.D. Professor Department of Preventive Medicine and Environmental Health University
More informationCurrent Asthma Management: Opportunities for a Nutrition-Based Intervention
Current Asthma Management: Opportunities for a Nutrition-Based Intervention Stanley J. Szefler, MD Approximately 22 million Americans, including 6 million children, have asthma. It is one of the most prevalent
More informationDiagnosis and Management of Asthma in Children based on the British Thoracic Society and Scottish Intercollegiate Guidelines Network September 2016
Diagnosis and Management of Asthma in Children based on the British Thoracic Society and Scottish Intercollegiate Guidelines Network September 2016 Diagnosis: There is no lower limit to the age at which
More informationII: Moderate Worsening airflow limitations Dyspnea on exertion, cough, and sputum production; patient usually seeks medical
Table 3.1. Classification of COPD Severity Stage Pulmonary Function Test Findings Symptoms I: Mild Mild airflow limitations +/ Chronic cough and sputum production; patient unaware of abnormal FEV 1 80%
More informationClinical trial efficacy: What does it really tell you?
Clinical trial efficacy: What does it really tell you? Joseph Spahn, MD Denver, Colo The primary goal of most clinical trials is an evaluation of the efficacy of the drug being evaluated. Therefore, it
More informationALLERGIC RHINITIS AND ASTHMA :
ALLERGIC RHINITIS AND ASTHMA : from the Link to Emerging Therapies Allergic rhinitis and asthma are both chronic heterogeneous disorders, with an overlapping epidemiology of prevalence, health care costs
More informationTips on managing asthma in children
Tips on managing asthma in children Dr Ranjan Suri Consultant in Respiratory Paediatrics Bupa Cromwell Hospital Clinics: Friday (pm) Asthma in Children Making the diagnosis Patterns of childhood asthma
More informationAsthma Therapy 2017 JOSHUA S. JACOBS, M.D.
Asthma Therapy 2017 JOSHUA S. JACOBS, M.D. BACKGROUND-PREVALENCE Asthma is one of the most common chronic diseases worldwide with an estimated 300 million affected individuals Prevalence is increasing
More informationCase-Compare Impact Report
Case-Compare Impact Report October 8, 20 For CME Activity: Developed through an independent educational grant from Genentech: Moderate to Severe Persistent Asthma: A Case-Based Panel Discussion (March
More informationDecramer 2014 a &b [21]
Buhl 2015 [19] Celli 2014 [20] Decramer 2014 a &b [21] D Urzo 2014 [22] Maleki-Yazdi 2014 [23] Inclusion criteria: Diagnosis of chronic obstructive pulmonary disease; 40 years of age or older; Relatively
More informationEvidence-based recommendations or Show me the patients selected and I will tell you the results
Respiratory Medicine (2006) 100, S17 S21 Evidence-based recommendations or Show me the patients selected and I will tell you the results Leif Bjermer Department of Respiratory Medicine & Allergology, 221
More informationAsthma training. Mike Levin Division of Asthma and Allergy Red Cross Hospital
Asthma training Mike Levin Division of Asthma and Allergy Red Cross Hospital Introduction Physiology Diagnosis Severity Treatment Control Stage 3 of guidelines Acute asthma Drug delivery Conclusion Overview
More informationScottish Medicines Consortium
Scottish Medicines Consortium budesonide/formoterol 100/6, 200/6 turbohaler (Symbicort SMART ) No. (362/07) Astra Zeneca UK Limited 9 March 2007 (Issued May 2007) The Scottish Medicines Consortium (SMC)
More informationStep-down approach in chronic stable asthma: A comparison of reducing dose Inhaled Formoterol/ Budesonide with maintaining Inhaled Budesonide.
Step-down approach in chronic stable asthma: A comparison of reducing dose Inhaled Formoterol/ Budesonide with maintaining Inhaled Budesonide. By: DR MOHD SHAMSUL AMRI Supervisor: Associate Professor Dr
More informationManagement of asthma in preschool children with inhaled corticosteroids and leukotriene receptor antagonists Leonard B. Bacharier
Management of asthma in preschool children with inhaled corticosteroids and leukotriene receptor antagonists Leonard B. Bacharier Department of Pediatrics, Division of Allergy and Pulmonary Medicine, Washington
More informationHCT Medical Policy. Bronchial Thermoplasty. Policy # HCT113 Current Effective Date: 05/24/2016. Policy Statement. Overview
HCT Medical Policy Bronchial Thermoplasty Policy # HCT113 Current Effective Date: 05/24/2016 Medical Policies are developed by HealthyCT to assist in administering plan benefits and constitute neither
More informationAsthma Update A/Prof. John Abisheganaden. Senior Consultant, Dept Of Respiratory & Crit Care Medicine Tan Tock Seng Hospital
Asthma Update - 2013 A/Prof. John Abisheganaden Senior Consultant, Dept Of Respiratory & Crit Care Medicine Tan Tock Seng Hospital Asthma A complex syndrome Multifaceted disease Heterogeneous Genetic and
More informationNG80. Asthma: diagnosis, monitoring and chronic asthma management (NG80)
Asthma: diagnosis, monitoring and chronic asthma management (NG80) NG80 NICE has checked the use of its content in this product and the sponsor has had no influence on the content of this booklet. NICE
More informationWho can get most benefit
Who can get most benefit from tiotropium in asthma? Y-M. Oh Asan Medical Center Univ. of Ulsan College of Medicine Seoul, Korea Tiotripium for Asthma 1 New in GINA 2015 Add-on tiotropium by soft-mist inhaler
More informationManagement of Bronchial Asthma in Adults..emerging role of anti-leukotriene
Management of Bronchial Asthma in Adults..emerging role of anti-leukotriene Han-Pin Kuo MD, PhD Department of Thoracic Medicine Chang Gung University Chang Gung Memorial Hospital Taipei, Taiwan Bronchial
More informationEfficacy and safety of montelukast in adults with asthma and allergic rhinitis
Respiratory Medicine (26), 1952 1959 Efficacy and safety of montelukast in adults with asthma and allergic rhinitis J.Chr. Virchow a,, C. Bachert b a Universität Rostock, Ernst-Heydemann-Str. 6, 1857 Rostock,
More informationEvaluation of Asthma Management in Middle EAst North Africa Adult population
STUDY REPORT SUMMARY Evaluation of Asthma Management in Middle EAst North Africa Adult population Descriptive study on the management of asthma in an asthmatic Middle East Africa adult population Background/Rationale:
More informationMeeting the Challenges of Asthma
Presenter Disclosure Information 11:05 11:45am Meeting the Challenge of Asthma SPEAKER Christopher Fanta, MD The following relationships exist related to this presentation: Christopher Fanta, MD: No financial
More informationCOPD or not COPD, that is the question.
COPD or not COPD, that is the question. Asthma-COPD Overlap Syndrome: ACOS Do we really need this? Michelle Harkins Disclosure Slide Slide help - William Busse, MD Organizational Interests ATS, ACCP, ACP
More informationInternational Journal of Medical Science and Education pissn eissn
COMPARISON OF MONTELUKAST AND KETOTIFEN AS ADD ON THERAPY IN MODERATE AND SEVERE PERSISTENT BRONCHIAL ASTHMA Dr. Gaurav Chhabra 1, Dr. Shubhakaran Sharma 2* Original research article 1,2 Associate professor,
More informationThe recent guidelines from the
...PRESENTATIONS... Adjunctive Therapy for Asthma: Treatment Options Robert A. Nathan, MD Abstract The National Heart, Lung, and Blood Institute guidelines on the diagnosis and management of asthma recommend
More informationTreatment with budesonide/formoterol pressurized metered-dose inhaler in patients with asthma: a focus on patient-reported outcomes
Patient Related Outcome Measures open access to scientific and medical research Open Access Full Text Article Review Treatment with budesonide/formoterol pressurized metered-dose inhaler in patients with
More informationDR REBECCA THOMAS CONSULTANT RESPIRATORY PHYSICIAN YORK DISTRICT HOSPITAL
DR REBECCA THOMAS CONSULTANT RESPIRATORY PHYSICIAN YORK DISTRICT HOSPITAL Definition Guidelines contact complicated definitions Central to this is Presence of symptoms Variable airflow obstruction Diagnosis
More informationAbstract Background Theophylline is widely used in the treatment of asthma, and there is evidence that theophylline has antiinflammatory
Thorax 2000;55:837 841 837 National Heart and Lung Institute, Imperial College School of Medicine and Royal Brompton Hospital, London SW3 6LY, UK S Lim A Jatakanon K F Chung P J Barnes Napp Laboratories
More informationTurning Science into Real Life Roflumilast in Clinical Practice. Roland Buhl Pulmonary Department Mainz University Hospital
Turning Science into Real Life Roflumilast in Clinical Practice Roland Buhl Pulmonary Department Mainz University Hospital Therapy at each stage of COPD I: Mild II: Moderate III: Severe IV: Very severe
More informationBudesonide treatment of moderate and severe asthma in children: A doseresponse
Budesonide treatment of moderate and severe asthma in children: A doseresponse study Soren Pedersen, MD, PhD, and Ove Ramsgaard Hansen, MD Kolding, Denmark Objective: The purpose of the study was to evaluate
More informationSHORT COMMUNICATION. Abstract. Kevin R. Murphy, 1 Tom Uryniak, 2 Ubaldo J. Martin 2 and James Zangrilli 2
SHORT COMMUNICATION Drugs R D 212; 12 (1): 9-14 1179-691/12/1-9 ª 212 Murphy et al., publisher and licensee Adis Data Information BV. This is an open access article published under the terms of the Creative
More informationProf Neil Barnes. Respiratory and General Medicine London Chest Hospital and The Royal London Hospital
Prof Neil Barnes Respiratory and General Medicine London Chest Hospital and The Royal London Hospital ASTHMA: WHEN EVERYTHING FAILS WHAT DO YOU DO? South GP CME 2013, Dunedin Saturday 17 th August 2013
More informationXolair (Omalizumab) Drug Prior Authorization Protocol (Medical Benefit & Part B Benefit)
Line of Business: All Lines of Business Effective Date: August 16, 2017 Xolair (Omalizumab) Drug Prior Authorization Protocol (Medical Benefit & Part B Benefit) This policy has been developed through review
More informationWhat s new in COPD? Apichart Khanichap MD. Department of Medicine, Faculty of Medicine, Thammasat university
What s new in COPD? Apichart Khanichap MD. Department of Medicine, Faculty of Medicine, Thammasat university Management stable COPD Relieve symptoms Improve exercise tolerance Improve health status Prevent
More informationSYNOPSIS THIS IS A PRINTED COPY OF AN ELECTRONIC DOCUMENT. PLEASE CHECK ITS VALIDITY BEFORE USE.
Drug product: Drug substance(s): Document No.: Edition No.: 1 Study code: Accolate Zafirlukast (ZD9188) 9188IL/0138 Date: 02 May 2007 SYNOPSIS A Multicenter, Randomized, Double-blind, -controlled, Parallel
More informationAllwin Mercer Dr Andrew Zurek
Allwin Mercer Dr Andrew Zurek 1 in 11 people are currently receiving treatment for asthma (5.4 million people in the UK) Every 10 seconds, someone is having a potentially life-threatening asthma attack
More informationWorld Journal of Pharmaceutical and Life Sciences WJPLS
wjpls, 2018, Vol. 4, Issue 10, 01-08 Research Article ISSN 2454-2229 Firas et al. WJPLS www.wjpls.org SJIF Impact Factor: 5.088 ASTHMA CONTROL Dr. Yaarub Madhloom Abbas 1, Dr. Firas Raad Shihab* 2 and
More informationAlberta Childhood Asthma Pathway for Primary Care
Asthma Diagnosis Box 1 Diagnosis: Based on symptom pattern, careful and thorough history of symptoms (wheeze, cough, night waking and activity limitations), and assessment of family history of asthma and
More informationGlobal Initiative for Asthma (GINA) What s new in GINA 2016?
Global Initiative for Asthma (GINA) What s new in GINA 2016? GINA Global Strategy for Asthma Management and Prevention GINA: A Brief History Established in 1993 Collaboration between NHLBI and WHO Multiple
More informationAsthma in Pregnancy. Asthma. Chronic Airway Inflammation. Objective Measures of Airflow. Peak exp. flow rate (PEFR)
Chronic Airway Inflammation Asthma in Pregnancy Robin Field, MD Maternal Fetal Medicine Kaiser Permanente San Francisco Asthma Chronic airway inflammation increased airway responsiveness to a variety of
More informationExhaled Nitric Oxide: An Adjunctive Tool in the Diagnosis and Management of Asthma
Exhaled Nitric Oxide: An Adjunctive Tool in the Diagnosis and Management of Asthma Jason Debley, MD, MPH Assistant Professor, Pediatrics Division of Pulmonary Medicine University of Washington School of
More informationDr Christopher Worsnop
Dr Christopher Worsnop Respiratory & Sleep Physician Austin Hospital, Melbourne Supported by: Top Tips in Modern Asthma Management Dr Christopher Worsnop Rotorua GPCME Meeting June 2013 Speaker declaration
More informationAsthma Management for the Athlete
Asthma Management for the Athlete Khanh Lai, MD Assistant Professor Division of Pediatric Pulmonary and Sleep Medicine University of Utah School of Medicine 2 nd Annual Sports Medicine Symposium: The Pediatric
More informationW e have shown in a previous meta-analysis of placebo
16 ASTHMA Clinical dose-response relationship of fluticasone propionate in adults with asthma M Masoli, M Weatherall, S Holt, R Beasley... See end of article for authors affiliations... Correspondence
More informationAsthma: Chronic Management. Yung-Yang Liu, MD Attending physician, Chest Department Taipei Veterans General Hospital April 26, 2015
Asthma: Chronic Management Yung-Yang Liu, MD Attending physician, Chest Department Taipei Veterans General Hospital April 26, 2015 Global Strategy for Asthma Management and Prevention Evidence-based Implementation
More informationmeasured Improvement in am PEFR FP vs BUD gave +11l/min FP vs BDP gave nonsignificant improvement in PEFR +3l/min FP: BUD ratio 1.
1 of 8 09/05/2018, 11:29 Guideline topic: Pharmacological management of asthma Evidence table 4.25: Budesonide vs Beclomethasone Different inhaled corticosteroids (ICS) flixotide propionate (FP) vs budesonide
More informationPharmacological Management of Obstructive Airways in Humans. Introduction to Scientific Research. Submitted: 12/4/08
Pharmacological Management of Obstructive Airways in Humans Introduction to Scientific Research Submitted: 12/4/08 Introduction: Obstructive airways can be characterized as inflammation or structural changes
More informationEvolution of asthma from childhood. Carlos Nunes Center of Allergy and Immunology of Algarve, PT
Evolution of asthma from childhood Carlos Nunes Center of Allergy and Immunology of Algarve, PT allergy@mail.telepac.pt Questionnaire data Symptoms occurring once or several times at follow-up (wheeze,
More informationPatient adherence to inhaled therapy A clinical perspective. Nicolas Roche Cochin, Site Val de Grâce University Paris Descartes, Paris, France
Patient adherence to inhaled therapy A clinical perspective Nicolas Roche Cochin, Site Val de Grâce University Paris Descartes, Paris, France 1 Disclosures Aerocrine Almirall AstraZeneca Boehringer Ingelheim
More informationThe ability of peak flow measurement
Lessons Learned From the Asthma Clinical Research Network By Brian Piazza, MS 2 and Timothy J. Craig, DO In 1993, the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health
More informationSYNOPSIS. Study center(s) This study was conducted in the United States (128 centers).
Drug product: Drug substance(s): Document No.: Edition No.: Study code: Date: SYMBICORT pmdi 160/4.5 µg Budesonide/formoterol SD-039-0725 17 February 2005 SYNOPSIS A Twelve-Week, Randomized, Double-blind,
More informationUpdate on Asthma & COPD. Stephen C. Lazarus, M.D. Division of Pulmonary & Critical Care Medicine University of California San Francisco
Update on Asthma & COPD Stephen C. Lazarus, M.D. Division of Pulmonary & Critical Care Medicine University of California San Francisco Advances in Primary Care Medicine October 27, 29 Disclosures No Pharma
More informationMontelukast vs. Inhaled Low-Dose Budesonide as Monotherapy in the Treatment of Mild Persistent Asthma: A Randomized Double Blind Controlled Trial
Montelukast vs. Inhaled Low-Dose Budesonide as Monotherapy in the Treatment of Mild Persistent Asthma: A Randomized Double Blind Controlled Trial by Vikram Kumar, a P. Ramesh, a Rakesh Lodha, a R. M. Pandey,
More informationChoosing an inhaler for COPD made simple. Dr Simon Hart Castle Hill Hospital
Choosing an inhaler for COPD made simple Dr Simon Hart Castle Hill Hospital 1 Declaration of interests I have received speaker fees, sponsorship to attend conferences, and funding for research from companies
More informationAsthma in Pregnancy. Michael Schatz, MD, MS Department of Allergy Kaiser Permanente Medical Center San Diego, CA. Introduction
Asthma in Pregnancy Michael Schatz, MD, MS Department of Allergy Kaiser Permanente Medical Center San Diego, CA Introduction Asthma is the most common potentially serious medical problem to complicate
More informationPersonalized medicine in childhood asthma. Dr Mariëlle Pijnenburg, Erasmus MC Sophia, Rotterdam, NL
Thank you for viewing this presentation. We would like to remind you that this material is the property of the author. It is provided to you by the ERS for your personal use only, as submitted by the author.
More informationPrimary Care Medicine: Concepts and Controversies Wed., February 17, 2010 Fiesta Americana Puerto Vallarta, Mexico Update on Asthma and COPD
Primary Care Medicine: Concepts and Controversies Wed., February 17, 2010 Fiesta Americana Puerto Vallarta, Mexico Update on Asthma and COPD Talmadge E. King, Jr., M.D. Krevins Distinguished Professor
More informationInhaled Corticosteroids for the Treatment of Chronic Asthma in Adults & Adolescents aged 12 years & over
Manufacturer Submission To The National Institute for Health and Clinical Excellence By GlaxoSmithKline UK Inhaled Corticosteroids for the Treatment of Chronic Asthma in Adults & Adolescents aged 12 years
More informationLong Term Care Formulary RS -29
RESTRICTED USE Asthma/COPD Management 1 of 6 PROTOCOL: Asthma Glossary of Medication Acronyms: SABA: short-acting beta agonist (e.g. salbutamol) SABD: short-acting bronchodilator (e.g. ipratropium or SABA)
More informationThe Acute & Maintenance Treatment of Asthma via Aerosolized Medications
The Acute & Maintenance Treatment of Asthma via Aerosolized Medications Douglas S. Gardenhire, EdD, RRT-NPS, FAARC Associate Professor and Chairman Department of Respiratory Therapy Objectives Define Asthma.
More informationIs reslizumab effective in improving quality of life and asthma control in adolescent and adult patients with poorly controlled eosinophilic asthma?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2018 Is reslizumab effective in improving
More informationImproving the Management of Asthma to Improve Patient Adherence and Outcomes
Improving the Management of Asthma to Improve Patient Adherence and Outcomes Robert Sussman, MD Atlantic Health System Overlook Medical Center Asthma Remains a Serious Health Risk in the US Every day in
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationAsthma for Primary Care: Assessment, Control, and Long-Term Management
Asthma for Primary Care: Assessment, Control, and Long-Term Management Learning Objectives After participating in this educational activity, participants should be better able to: 1. Choose the optimal
More informationรศ. นพ. ว ชรา บ ญสว สด M.D., Ph.D. ภาคว ชาอาย รศาสตร คณะแพทยศาสตร มหาว ทยาล ยขอนแก น
รศ. นพ. ว ชรา บ ญสว สด M.D., Ph.D. ภาคว ชาอาย รศาสตร คณะแพทยศาสตร มหาว ทยาล ยขอนแก น COPD Guideline Changing concept in COPD management Evidences that we can offer COPD patients better life COPD Guidelines
More informationGetting Asthma treatment right. Dr David Cremonesini Specialist Pediatrician American Hospital
Getting Asthma treatment right Dr David Cremonesini Specialist Pediatrician American Hospital cdavid@ahdubai.com } Consultant Paediatrician from UK of 5.5 years } Speciality in Allergy / Asthma (PG Certificate)
More informationAdult Summary flowchart for Asthma Switch and Step Down to ENHCCG preferred inhaler choices
ENHCCG Adult Asthma Switch and Step Down Algorithms - Approved by Hertfordshire Medicines Management Committee June 2016 Page 1 of 6 Adult Summary flowchart for Asthma Switch and Step Down to ENHCCG preferred
More informationAsthma Upate 2018: What s New Since the 2007 Asthma Guidelines of NAEPP?
10:50-11:50am Asthma Update 2018: What s New Since the 2007 National Asthma Guidelines? SPEAKER Christopher H. Fanta, MD Disclosures The following relationships exist related to this presentation: Christopher
More informationT he use of inhaled corticosteroids to control the inflammatory
791 ORIGINAL ARTICLE Early asthma control and maintenance with eformoterol following reduction of inhaled corticosteroid dose D Price, D Dutchman, A Mawson, B Bodalia, S Duggan, P Todd on behalf of the
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationDifficult Asthma Assessment: A systematic approach
Difficult Asthma Assessment: A systematic approach Dr Naghmeh Radhakrishna Respiratory, Sleep & Allergy Physician Allergy, Asthma & Clinical Immunology Service The Alfred Hospital Melbourne, Australia
More informationIn 2002, it was reported that 72 of 1000
REPORTS Aligning Patient Care and Asthma Treatment Guidelines Eric Cannon, PharmD Abstract This article describes how the National Asthma Education and Prevention Program Guidelines for the Diagnosis and
More informationCHAPTER 5. Weekly self-monitoring and treatment adjustment benefit patients with partly controlled and uncontrolled asthma
CHAPTER 5 Weekly self-monitoring and treatment adjustment benefit patients with partly controlled and uncontrolled asthma Victor van der Meer, Henk F. van Stel, Moira J. Bakker, Albert C. Roldaan, Willem
More informationGuideline topic: Pharmacological management of asthma Evidence table 4.11b: Add-on drugs for inhaled steroids: Long acting or oral B2 agonists
1 of 8 09/05/2018, 11:41 Guideline topic: Pharmacological management of asthma Evidence table 4.11b: Add-on drugs for steroids: Long acting or oral B2 agonists Author Year Study type Quality rating Population
More informationAirways hyperresponsiveness to different inhaled combination therapies in adolescent asthmatics
Airways hyperresponsiveness to different inhaled combination therapies in adolescent asthmatics Daniel Machado 1, MD Celso Pereira 1,2, MD, PhD Beatriz Tavares 1, MD Graça Loureiro 1, MD António Segorbe-Luís
More information«Impact of a pharmaceutical intervention to improve adherence of inhaled medication in asthma and COPD patients»
«Impact of a pharmaceutical intervention to improve adherence of inhaled medication in asthma and COPD patients» Baseline data from a randomized controlled trial 5 th Swiss Health Services Research Symposium,
More informationAdherence to asthma controller medication regimens
Respiratory Medicine (2005) 99, 1263 1267 Adherence to asthma controller medication regimens D.A. Stempel a,, S.W. Stoloff b, J.R. Carranza Rosenzweig c, R.H. Stanford c, K.L. Ryskina d, A.P. Legorreta
More informationAsthma in Pediatric Patients. DanThuy Dao, D.O., FAAP. Disclosures. None
Asthma in Pediatric Patients DanThuy Dao, D.O., FAAP Disclosures None Objectives 1. Discuss the evaluation and management of asthma in a pediatric patient 2. Accurately assess asthma severity and level
More information